Lytix Biopharma announces expansion of the ATLAS-IT-05 study to Europe

Oslo, 14 November 2022. Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company, today announces site activation for the ATLAS-IT-05 study in three European countries.ATLAS-IT-05 is a Phase II combination study evaluating LTX-315 and pembrolizumab in patients with advanced melanoma. The study was initiated at MD Anderson Cancer Center in 2021 and is currently ongoing in the US. The objective of the study is to document whether LTX-315 in combination with pembrolizumab is effective in inducing tumor responses in patients who have failed prior anti PD 1/PD